Richmond Pharmacologys latest research on the effect of food on the QT interval Presented at the 6th European Congress of Pharmacology 2012

Posted:
1
June 2012

Food alters the QTc and might be an attractive non-pharmacological method of confirming assay sensitivity in Thorough QT (TQT) studies. This idea was recently examined (Taubel et al., 2011) and showed that food shortens QTcF. This is important because previously it has been debated in the literature to whether euglycaemic hyperinsulinemia can prolong the QTc interval (Gastaldelli et al. 2000).The European Congress of Pharmacology will be hosted this year by the Spanish Society of Pharmacology in Granada, Spain from 17-20 July, and will bring together pharmacologists from all over the world to debate current drug research and development issues from �bench to bedside�.Following Dr Taubel�s presentation  at the DIA 3rd Cardiac Safety Workshop in Japan, he will present his latest data assessing how late changes  i.e. 2-4 hours after the end of a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects. The presentation will be based on a single centre, randomised, placebo- and positive-controlled study that was carried out by Richmond Pharmacology in both healthy Caucasian and Japanese subjects. The euglycaemic insulin clamp was used to investigate the effects of insulin, C-peptide and glucose on the QT interval.View the Scientific Program

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more